Horizon Discovery, H3 Bio Launch Screening Program for Oncology Targets | GenomeWeb

NEW YORK (GenomeWeb News) – Horizon Discovery and H3 Biomedicine today launched SyntheTx, a technology partnership created to provide novel oncology targets and early-stage drug discovery programs to drug manufacturers.

H3 Biomedicine, a Cambridge, Mass.-based biopharmaceutical firm, is the first partner in the program. Additional partners will be sought in the first 12 to 18 months of the program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.